The £198 Million Cash Pile That Has ITM Power’s Bulls and Bears at War

ITM Power shares hit 166.50p, yet average analyst target is 98.64p. Retail investors cash out as institutions eye 2028 break-even and a key UK subsidy decision in June.

The numbers are hard to reconcile. ITM Power’s shares have surged roughly 400 percent over the past twelve months, touching a fresh 52-week high of 166.50 pence. The market capitalisation now sits just north of £1 billion. Yet the average analyst price target stands at a mere 98.64 pence — a chasm between what the crowd believes and what the professionals are willing to underwrite.

That gap has created one of the most polarised trades in the British clean-energy space. On one side stand retail investors, many of whom rode the stock from around 30 pence in May 2025 past the 150-pence mark and are now cashing out in droves. On the other side sit institutions like Morgan Stanley, which rates the shares “Overweight” with a 170-pence target and sees an operational break-even arriving as early as fiscal 2028 — a full year ahead of consensus.

The divergence played out in plain sight on a single trading day recently, when 13.2 million shares changed hands — 168 percent above the daily average — and the stock slid back to 143.30 pence. On the AJ Bell platform, ITM Power briefly topped the sell list, with roughly one in every fifty sell orders directed at the hydrogen specialist, outpacing even blue chips such as Shell and AstraZeneca.

A Business That’s Improving — But Still Bleeding

The operational story has genuinely brightened. For the first half of fiscal 2026, ITM Power reported record revenue of £18 million, of which £15.5 million came from equipment sales and the remainder from engineering studies, spare parts and maintenance contracts. Management responded by lifting the full-year guidance to as much as £43 million.

The order book now stands at £152 million, and crucially, 71 percent of those contracts are considered profitable — a sign that the company is steadily shedding the low-margin legacy deals that dragged on earlier performance. Analysts at Zeus Capital point to a comfortable cash cushion of roughly £198 million, and the company carries no debt.

Yet profitability remains elusive. The operating loss is expected to land around £30 million, and the pre-tax loss for the year ending April 2025 widened to £45.4 million. The question is whether the improving trajectory can close that gap before the cash pile runs down.

The June Decision That Could Change Everything

All eyes are now on a subsidy ruling expected in June. The UK government, through its state-backed entity Great British Energy, has proposed a £40 million equity injection — which would give it roughly a 10 percent stake — alongside a direct grant of £46.5 million. The funds are earmarked for a new production line in Sheffield dedicated to the Chronos electrolyser platform.

Chronos is the centrepiece of the bull case. Each unit delivers two megawatts — triple the output of the current Trident system — while cutting costs by 40 percent. Management plans to make a final investment decision on the Sheffield line immediately after the subsidy verdict, with a target of one gigawatt of annual capacity by 2028.

A positive outcome would allow ITM Power to place orders for the Chronos line and lock in a commercial launch for 2028. A delay would throw the entire timeline into doubt.

Military Ambitions and Civilian Scale

Beyond Chronos, the company is pursuing a dual-track growth strategy that blends civilian hydrogen projects with defence applications. A partnership with Rheinmetall targets the Giga-PtX project, envisaging several hundred decentralised plants across Europe, each with up to 50 megawatts of electrolysis capacity, to produce synthetic fuels for NATO forces.

On the civilian side, ITM has secured agreements in Germany with RWE and the Stablegrid Group covering projects totalling more than 710 megawatts. Pending investment decisions on large-scale developments such as Uniper’s Humber project could further swell the order book in the near term.

The Analyst Split

The consensus rating is technically a “Buy” — seven analysts recommend buying, four say hold, and one says sell. But the price targets tell a more cautious story. UBS holds firm at 60 pence, warning that the valuation has run far ahead of fundamentals. A price-to-sales ratio of roughly 38 lends weight to that scepticism.

Morgan Stanley stands as the most prominent outlier, arguing that lower assumed capital costs and an improved risk profile justify an earlier break-even. The bank sees a path to operational profitability by fiscal 2028, a year before the broader market expects it.

The June update — subsidy decision and all — will determine which camp has read the situation correctly. If the funding comes through and Chronos moves into production, the rally may prove to have been more than just momentum. If not, the gap between the share price and the analyst consensus will look less like a disagreement and more like a warning.